Subclinical HPV infection more prevalent in sexually inactive young girls than thought, say positive HPV DNA test results.
Positive tests for human papillomavirus (HPV) in young girls who were not yet sexually active suggest a wider subclinical prevalence of HPV infection than previously thought, according to a study reported in the May issue of the American Journal of Obstetrics and Gynecology.
Daniela Doerfler, MD, of the Medical University of Vienna in Austria, and colleagues took anogenital specimens from 114 girls aged 4 to 15 prior to coitarche, who came to a gynecological clinic for various problems. After examination, four girls were excluded from the study because of sexual abuse. The specimens were tested for HPV.
The researchers detected low-risk HPV-deoxyribonucleic acid (DNA) in four of the girls (3.6%) and high-risk HPV DNA in 15 of the girls (13.6%). Two of the girls with a positive test also had genital warts. At 1-year follow-up, two of the girls still had high-risk HPV DNA, while one girl who previously tested positive for high-risk HPV DNA had low-risk HPV DNA.
"Our study demonstrates for the first time that subclinical HPV infection is also common in girls prior to coitarche without any history of sexual abuse or consensual sexual activity. Therefore, we recommend being very careful when suspecting sexual abuse only on the basis of positive HPV testing. On the other hand, HPV testing in population-based representative sample of young girls could be crucial to decide whether vaccination against HPV at a younger age is more beneficial than the current practice," the authors write.
Doerfler D, Bernhaus A, Kottmel A, et al. Human papillomavirus infection prior to coitarche. Am J Obstet Gynecol. 2009;200:487.e1-487.e5.
Increase in ED visits for hypertensive disorders from 2006 to 2020 reported
September 18th 2024In a recent study, reported rates on emergency department utilization for hypertensive disorders of pregnancy and the postpartum period were higher in 2020 than 2006, with rates especially high among non-Hispanic Black, Hispanic, and Asian patients.
Read More
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More